Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670216 | 0.86 | MEN1 (0.47) | NPC1RAB9ASLC6A2SLC6A4KDM4E | |
| SCHEMBL15068444 | 0.83 | CYP3A4 (0.39) | NPC1RAB9ASLC6A2SLC6A4KDM4E | |
| SCHEMBL27438368 | 0.81 | ACHE (0.48) | NPC1RAB9AKMT2AMEN1POLB | |
| SCHEMBL3686228 | 0.80 | KMT2A (0.45) | NPC1SLC6A2SLC6A4KDM4ETDP1 | |
| SCHEMBL25385728 | 0.80 | ADRA2A (0.33) | NPC1RAB9A | |
| SCHEMBL30378110 | 0.80 | ADRA2A (0.33) | NPC1RAB9A | |
| SCHEMBL829699 | 0.79 | MAPT (0.44) | NPC1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL25385149 | 0.79 | MAOB (0.47) | NPC1RAB9ASLC6A4 | |
| SCHEMBL5259483 | 0.78 | MAPT (0.43) | NPC1RAB9AKDM4EKMT2AMEN1 | |
| SCHEMBL6040717 | 0.77 | HTR2C (0.47) | NPC1RAB9AKDM4EALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3811944-B1 | PYRAZINE DERIVATIVE AS CHK1 INHIBITOR | SENTINEL ONCOLOGY LTD (GB) | 2025-07-16 | — | — | EP | disclosed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2022253907-A1 | PHARMACEUTICAL SALTS OF A CHK-1 INHIBITOR | SENTINEL ONCOLOGY LIMITED (GB) | 2022-12-08 | — | — | WO | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20130090498-A1 | PROCESSES FOR PRODUCING 4-BROMO-2-METHOXYBENZALDEHYDE | ALBEMARLE CORPORATION (US) | 2013-04-11 | — | — | US | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| EP-2441763-A1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | Glaxo Group Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012009173-A1 | PROCESSES FOR PRODUCING 4-BROMO-2-METHOXYBENZALDEHYDE | ALBEMARLE CORPORATION (US) | 2012-01-19 | — | — | WO | disclosed |
| CN-102112465-A | Crystalline forms of 6- [ (4S) -2-methyl-4- (2-naphthyl) -1,2,3, 4-tetrahydroisoquinolin-7-yl ] pyridazin-3-amine | BRISTOL MYERS SQUIBB CO | 2011-06-29 | — | — | CN | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| EP-1907374-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012479-A2 | BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
| CN-1129604-C | Amino acid derivatives and their use as thrombin inhibitors | ASTRA AB (SE) | 2003-12-03 | — | — | CN | disclosed |
| CN-1226895-A | Amino acid derivatives and their use as thrombin inhibitors | ASTRA AB (SE) | 1999-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | NPC1 4266/4885RAB9A 1322/4885SLC6A2 4834/4885 |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | NPC1 840/4885RAB9A 2456/4885SLC6A2 1059/4885 |
| US-20130090498-A1 | PROCESSES FOR PRODUCING 4-BROMO-2-METHOXYBENZALDEHYDE | KCNMB4, KCNB1, KCNMB1 | NPC1 3625/4885RAB9A 4149/4885SLC6A2 1967/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | NPC1 306/4885RAB9A 1682/4885SLC6A2 4348/4885 |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | NPC1 306/4885RAB9A 1682/4885SLC6A2 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.